ORIC Pharmaceuticals Bundle
What is the history of ORIC Pharmaceuticals?
ORIC Pharmaceuticals is a clinical-stage biopharmaceutical company focused on overcoming resistance in cancer. Founded in 2014, it aims to develop novel small molecule therapies for challenging cancers.
The company's mission is to tackle drug resistance, a major hurdle in cancer treatment, by creating innovative solutions for patients with difficult-to-treat conditions.
ORIC Pharmaceuticals was established with the core mission of 'Overcoming Resistance In Cancer' (ORIC). This foundational principle drives its pursuit of novel small molecule therapies designed to combat various forms of cancer drug resistance, including those in hormone-dependent cancers and precision oncology. As of July 23, 2025, the company's market capitalization stands at approximately $1.01 billion, underscoring its significant presence in the biopharmaceutical industry. The development of treatments like ORIC Pharmaceuticals BCG Matrix exemplifies their commitment to advancing cancer care.
What is the ORIC Pharmaceuticals Founding Story?
The ORIC Pharmaceuticals company history began in 2014, with its establishment in South San Francisco, California. The company was founded by a distinguished group of scientists who recognized a significant challenge in cancer treatment: the emergence of drug resistance.
ORIC Pharmaceuticals Founding Story
ORIC Pharmaceuticals was founded in 2014 by a team of leading scientists, including Charles Sawyers, Scott Lowe, Kevan Shokat, and Jay Bradner. Richard A. Heyman, with prior experience co-founding Aragon and Seragon Pharmaceuticals, also contributed as a co-founder, bringing expertise in hormone-dependent cancer therapeutics. The company's origin story is rooted in addressing the critical issue of drug resistance in cancer therapy.
- Established in 2014 in South San Francisco, California.
- Founded by accomplished scientists Charles Sawyers, Scott Lowe, Kevan Shokat, and Jay Bradner.
- Richard A. Heyman, a co-founder of Aragon and Seragon Pharmaceuticals, also joined as a co-founder.
- The primary mission was to develop therapies that overcome drug resistance in cancer.
- Initial focus on small molecule therapies targeting resistance mechanisms.
- Secured $50 million in Series A financing in October 2016, led by Foresite Capital.
- Significant participation in the Series A round included Taiho Ventures, Boxer Capital, and Alexandria Venture Investments.
- Early development efforts included a small molecule antagonist of the glucocorticoid receptor (GR), later known as ORIC-101.
- The company's journey reflects a commitment to advancing oncology treatments by tackling resistance.
- Understanding the Competitors Landscape of ORIC Pharmaceuticals is crucial for appreciating its strategic positioning.
ORIC Pharmaceuticals SWOT Analysis
- Complete SWOT Breakdown
- Fully Customizable
- Editable in Excel & Word
- Professional Formatting
- Investor-Ready Format
What Drove the Early Growth of ORIC Pharmaceuticals?
ORIC Pharmaceuticals embarked on a significant growth phase following its initial funding, rapidly expanding its research and development capabilities and clinical trial initiatives.
Early Funding Rounds Fuel Expansion
After its Series A in October 2016, ORIC Pharmaceuticals secured a substantial $120 million in a Series B financing round in 2018. This capital infusion, co-led by prominent investors, was instrumental in advancing the company's research and development pipeline and initiating crucial clinical studies, marking a key step in the ORIC Pharmaceuticals company journey.
Strategic Pipeline and IP Growth
In 2017, ORIC enhanced its intellectual property through an exclusive license with the University of Michigan. A pivotal moment in the ORIC Pharmaceuticals history occurred in 2019 with the acquisition of Voronoi's HCC4006 program, adding a mutant-selective EGFR inhibitor to its pipeline for non-small cell lung cancer.
IPO and Clinical Development Acceleration
The company achieved a significant milestone with its Initial Public Offering (IPO) in April 2020, raising $120 million. This provided the necessary financial resources to accelerate its clinical development programs and support the ORIC Pharmaceuticals evolution over time.
Financial Strength and Leadership Appointments
By December 31, 2024, ORIC reported $256 million in cash and investments, further bolstered by a $125 million private placement in May 2025, extending its funding runway. Key leadership appointments, including Jacob Chacko, M.D., as President and CEO and Keith Lui as Senior Vice President of Commercial and Medical Affairs in Q2 2024, underscore the company's strategic direction and commitment to its Mission, Vision & Core Values of ORIC Pharmaceuticals.
ORIC Pharmaceuticals PESTLE Analysis
- Covers All 6 PESTLE Categories
- No Research Needed – Save Hours of Work
- Built by Experts, Trusted by Consultants
- Instant Download, Ready to Use
- 100% Editable, Fully Customizable
What are the key Milestones in ORIC Pharmaceuticals history?
ORIC Pharmaceuticals has navigated a path marked by significant clinical advancements and strategic collaborations, alongside the inherent challenges of a biopharmaceutical company. The company's journey highlights a commitment to data-driven decisions and focused development, as seen in its pipeline progression and financial management. This Growth Strategy of ORIC Pharmaceuticals outlines key moments in its history.
| Year | Milestone |
|---|---|
| 2022 | Discontinued development of ORIC-101 following Phase 1b trial results. |
| 2024 | Presented preclinical data for ORIC-944 at the AACR Annual Meeting. |
| 2025 | Secured $125 million in private placement financing in May. |
| 2025 | Advanced ORIC-114 into expansion cohorts of Phase 1b trials. |
Key innovations include ORIC-944, a selective allosteric inhibitor of PRC2 in Phase 1b trials for metastatic castration-resistant prostate cancer, and ORIC-114, a brain-penetrant EGFR/HER2 inhibitor advancing in trials for NSCLC.
ORIC-944 Development
ORIC-944 is a potent and selective allosteric inhibitor of PRC2, currently in Phase 1b trials for metastatic castration-resistant prostate cancer. Preclinical data from 2024 demonstrated its favorable drug properties and synergistic potential with androgen receptor pathway inhibitors.
ORIC-114 Advancement
ORIC-114, a brain-penetrant EGFR/HER2 inhibitor, has entered expansion cohorts in Phase 1b trials for patients with mutated NSCLC. A significant partnership with Johnson & Johnson is evaluating ORIC-114 in combination therapy for first-line NSCLC.
ORIC-533 Potential
ORIC-533 is an orally bioavailable CD73 inhibitor being developed for multiple myeloma. Early data suggests promising safety and efficacy, with strategic collaborations being sought for combination studies.
ORIC-613 Pipeline Asset
ORIC's discovery pipeline includes ORIC-613, a selective PLK4 inhibitor. Preclinical data for this asset was presented in 2024, indicating ongoing research and development efforts.
The company has faced challenges, including the discontinuation of its ORIC-101 program in March 2022 due to insufficient clinical activity, which impacted its stock. Financially, as a pre-revenue entity, it has reported net losses, with a notable increase in research and development expenses.
Program Discontinuation Impact
The decision to discontinue ORIC-101 in 2022, based on Phase 1b trial data, led to a significant market reaction. This event underscored the high-risk, high-reward nature of clinical-stage biopharmaceutical development.
Financial Performance
The company reported a net loss of $127.8 million in 2024, an increase from $100.7 million in 2023, largely driven by rising R&D expenditures. First quarter 2025 R&D expenses reached $24.6 million, up from $22.0 million in the prior year's period.
Navigating Pre-Revenue Status
As a pre-revenue company, maintaining financial stability is a continuous challenge. However, securing substantial financing, such as the $125 million private placement in May 2025, demonstrates resilience and investor confidence.
ORIC Pharmaceuticals Business Model Canvas
- Complete 9-Block Business Model Canvas
- Effortlessly Communicate Your Business Strategy
- Investor-Ready BMC Format
- 100% Editable and Customizable
- Clear and Structured Layout
What is the Timeline of Key Events for ORIC Pharmaceuticals?
The ORIC Pharmaceuticals history showcases a journey of strategic development and adaptation, beginning with its founding in 2014. The company has navigated significant milestones, including substantial financing rounds and pipeline expansions, alongside challenges that have shaped its trajectory. This ORIC Pharmaceuticals company overview highlights its evolution and commitment to advancing cancer therapies.
| Year | Key Event |
|---|---|
| 2014 | ORIC Pharmaceuticals was founded in South San Francisco, CA. |
| October 2016 | The company completed its Series A financing, securing $50 million. |
| 2017 | An exclusive license agreement was entered into with the University of Michigan. |
| 2018 | ORIC Pharmaceuticals closed a $120 million Series B financing round. |
| 2019 | The company acquired Voronoi's HCC4006 program, broadening its pipeline. |
| April 2020 | An Initial Public Offering (IPO) was completed, raising $120 million. |
| March 2022 | The lead program, ORIC-101, was discontinued due to insufficient clinical activity. |
| June 2023 | A private placement raised $85 million for the company. |
| January 2024 | The company secured $125 million through a private placement of common stock. |
| First Half 2024 | ORIC-944 began dosing in a Phase 1b trial for prostate cancer in combination with NUBEQA® and ERLEADA®. |
| 2024 AACR Annual Meeting | Preclinical data for ORIC-944 and ORIC-613 were presented. |
| December 31, 2024 | Cash and investments totaled $256 million. |
| January 13, 2025 | Early Phase 1b combination data for ORIC-944 were provided. |
| February 18, 2025 | Q4 and full-year 2024 financial results were reported. |
| May 5, 2025 | Q1 2025 financial results were reported, with cash and investments of $223.8 million. |
| May 28, 2025 | A $125 million private placement financing was announced, extending the cash runway into late 2027. |
Advancing Key Pipeline Programs
The company is focused on the advancement of its lead programs, ORIC-944 and ORIC-114. Multiple data readouts are anticipated over the next 15 to 18 months for both clinical programs.
Strategic Clinical Development Milestones
A significant future step includes the planned initiation of the first Phase 3 trial for ORIC-944 in mCRPC in the first half of 2026. Registrational development for ORIC-114 in first-line NSCLC is expected to begin later in 2026.
Robust Financial Position and Runway
The company's financial strategy is supported by a strong cash position. With cash and investments expected to fund operations into late 2027, ORIC Pharmaceuticals is well-positioned for its upcoming development phases.
Positive Analyst Sentiment and Investor Engagement
Analysts have shown a bullish outlook, with average price targets indicating significant potential upside. The company actively engages in investor conferences to share progress and future plans, reflecting its founding vision.
ORIC Pharmaceuticals Porter's Five Forces Analysis
- Covers All 5 Competitive Forces in Detail
- Structured for Consultants, Students, and Founders
- 100% Editable in Microsoft Word & Excel
- Instant Digital Download – Use Immediately
- Compatible with Mac & PC – Fully Unlocked
- What is Competitive Landscape of ORIC Pharmaceuticals Company?
- What is Growth Strategy and Future Prospects of ORIC Pharmaceuticals Company?
- How Does ORIC Pharmaceuticals Company Work?
- What is Sales and Marketing Strategy of ORIC Pharmaceuticals Company?
- What are Mission Vision & Core Values of ORIC Pharmaceuticals Company?
- Who Owns ORIC Pharmaceuticals Company?
- What is Customer Demographics and Target Market of ORIC Pharmaceuticals Company?
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.